A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor
Status:
Recruiting
Trial end date:
2024-08-15
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2
study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and
preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination
with a PD-1 inhibitor in subjects with advanced solid tumors.